 Adverum Biotechnologies NASDAQ: ADVM shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema. The safety of every patient who is participating in our clinical studies with our gene therapy is the utmost priority for us at Adverum, said Laurent Fischer, M.D. 